Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
复制标题
DOI：
10.1016/j.amjcard.2010.09.031
复制
发表时间：
2011-02-01
期刊：
影响因子：
--
通讯作者：
Schaefer EJ
中科院分区：
文献类型：
--
作者：
Thongtang N;Ai M;Otokozawa S;Himbergen TV;Asztalos BF;Nakajima K;Stein E;Jones PH;Schaefer EJ
研究报告称，与安慰剂相比，接受他汀类药物的受试者发生糖尿病的风险增加。我们的目的是比较最大剂量瑞舒伐他汀和阿托伐他汀对高血压患者血浆胰岛素、糖化白蛋白（GA）、脂联素（ADN）和C反应蛋白（CRP）水平与基线水平的影响。我们研究了252名高血脂症男性和女性，他们随机接受阿托伐他汀80 mg/天或瑞舒伐他汀40 mg/天治疗6周。阿托伐他汀和瑞舒伐他汀在降低低密度脂蛋白胆固醇（LDL-C）和甘油三酯（TG）水平方面均高度有效，瑞舒伐他汀在升高高密度脂蛋白胆固醇（HDL-C）方面比阿托伐他汀更有效。阿托伐他汀和瑞舒伐他汀在最大剂量时均显著（p<0.05）使中位胰岛素水平分别较基线升高5.2%和8.7%。然而，仅阿托伐他汀使GA水平较基线升高（阿托伐他汀为+0.8% vs瑞舒伐他汀为-0.7%，p=0.002）。与基线值相比，阿托伐他汀和瑞舒伐他汀均导致CRP显著（p<0.001）和相似的中位降低，分别为−40%和−26%。然而，两组之间ADN较基线的变化无统计学显著差异（−1.5% vs − 4.9%，p=0.15）。总之，我们的数据表明，最大剂量的阿托伐他汀或瑞舒伐他汀治疗显著降低CRP水平，但也适度增加胰岛素水平。
Studies have reported an increased risk of developing diabetes in subjects receiving statins versus placebo. Our purpose was to compare the effects of maximal doses of rosuvastatin and atorvastatin on plasma levels of the insulin, glycated albumin (GA), adiponectin (ADN), and C reactive protein (CRP) versus baseline in hyperlipidemic patients. We studied 252 hyperlipidemic men and women who were randomized to receive atorvastatin 80 mg/day or rosuvastatin 40 mg/day over a 6-week period. Atorvastatin and rosuvastatin were both highly effective in lowering low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels, with rosuvastatin being more effective than atorvastatin in raising high density lipoprotein cholesterol (HDL-C). Atorvastatin and rosuvastatin at maximum dosage both significantly (p<0.05) raised median insulin levels by 5.2% and 8.7% respectively from baseline. However, only atorvastatin increased GA levels from baseline (+0.8% for atorvastatin vs −0.7% for rosuvastatin, p=0.002). Both atorvastatin and rosuvastatin caused significant (p<0.001) and similar median reductions in CRP of −40% and −26% as compared to baseline values respectively. However, there was no statistical significant difference between the two groups in ADN changes from baseline (−1.5% vs −4.9%, p=0.15). In conclusion, our data indicated that maximum dosage of atorvastatin or rosuvastatin therapy significantly lower CRP levels, but also moderately increase insulin levels.